GeneQiming Celebrates Groundbreaking of iNKT Cell Therapy GMP Facility

Recently, the GMP factory construction project of Beijing Gene Key Life Technology Co., Ltd. has celebrated its groundbreaking!

Groundbreaking Ceremony for Beijing Gene Key Life Technology Co., Ltd's GMP Facility Construction Project Held in Zhongguancun(Daxing)Building 11 of the Cell Gene Therapy Industry Park was grandly held, attended by Li Haitao, Deputy General Manager of Daxing Biomedical Industry Base Management Committee, representatives of COFCO Group, and Zhongguancun.(Daxing)Luo Zhen, Assistant General Manager of the Cell Gene Therapy Industrial Park, Feng Jikai, Chairman of Beijing Gene Key Life Technology Co., Ltd., shareholder representatives General Manager Zhang and General Manager Zhao attended the event in person. Founding shareholder Xie Hang sent a congratulatory message to jointly witness this milestone moment for Gene Key.

As Zhongguancun(Daxing)The benchmark project that the Cell and Gene Therapy Industrial Park focuses on introducing, the GMP production workshop of Beijing Gene Key Life Technology Co., Ltd.'s iNKT cells, will be constructed according to the highest international standards, achieving a remarkable transformation from "iNKT cell research and development laboratory – iNKT cell pilot platform – iNKT cell pharmaceutical production," accelerating the progression of iNKT cell therapy products from the laboratory to the market, benefiting patients with solid tumors such as liver cancer and pancreatic cancer.

Zhongguancun(Daxing)The Cell and Gene Therapy Industrial Park, as the first characteristic industrial park in Beijing focusing on cell and gene therapy, opened in September 2024. It is committed to building an internationally influential CGT scientific innovation hub. The park has attracted one Nobel laureate, seven academicians, and multiple core platform technologies in the field of cell and gene therapy. It continues to build a complete industrial chain ecosystem for cell and gene therapy and new vaccines, exploring an integrated development model of education, technology, and talent. It aims to create a globally influential hub for scientific innovation, talent, and industry.

Vice General Manager Li Haitao stated:"Daxing Biomedical Base will rely on Zhongguancun(Daxing)The cluster advantage of the Cell and Gene Therapy Industrial Park provides projects with a policy fast track, priority resource allocation, and full-cycle service support, helping them become industry benchmarks.

COFCO Group Representative, Zhongguancun(Daxing)Luo Zhen, Assistant General Manager of the Cell Gene Therapy Industrial Park, emphasized:"COFCO Group will fully leverage its strategic investment advantages to accelerate the rapid development of Gene Key Life Technology through capital empowerment, industrial synergy, and the introduction of international resources, thereby enhancing industrial competitiveness."

Feng Jikai, Chairman of Beijing Gene Key Life Technology Co., Ltd, thanked all parties for their support and expressed:"The project will adopt intelligent production systems and international advanced quality control standards, relying on Zhongguancun."(Daxing)The Advantages of the Cell and Gene Therapy Industrial Park Platform Accelerate the Market Entry and Industrialization Process of Innovative Drugs.

Zhang Hailong, representative of the construction party, promised:"Will allocate an 'elite team + cutting-edge equipment' to ensure project quality with 'precision engineering', and guarantee construction progress through 'node control', assisting the project to commence operations and achieve effectiveness as soon as possible."

As an innovative pioneer in the field of cell and gene therapy, Beijing Gene Key Life Technology Co., Ltd.'s construction of the GMP facility will significantly enhance the company's R&D transformation capabilities and industrialization process. Meanwhile, Zhongguancun(Daxing)The "ecological empowerment" of the Cell and Gene Therapy Industrial Park, the "policy support" from Daxing Biomedical Base, the "industrial synergy" of COFCO Group, and the "precision engineering guarantee" from the construction team will solidify the foundation for the project's development.

With the successful conclusion of the groundbreaking ceremony, the GMP facility construction project of Beijing Gene Key Life Technology Co., Ltd. has officially entered the construction phase. In the future, with the full collaboration of the government, COFCO, and Gene Key, Gene Key will become a shining star in China's Medical Valley, injecting strong momentum into the development of China's cell therapy industry and bringing innovative treatments to new heights for patients worldwide.

At the IBI EXPO 2025 Biopharmaceutical Innovation Industry Conference held in early March this year"The 4th General Cell Drug Development Forum"" , Chief Medical Officer Lu Cheng of Beijing Gene Key Life Technology Co., Ltd. shared"The Potential and Research Progress of Autologous & Allogeneic iNKT in the Treatment of Solid Tumors"", scientifically explaining the potential of the company's globally leading cell drug in combating pancreatic cancer and other solid tumors."

Exciting Live Broadcast Preview

Press and hold to scan the QR code to participate immediately ↓

Swipe up to view

Recommendation 1

April 17 (Thursday) 19:00 - 20:30

From Plasmids to Transfection: Breakthroughs in Key Raw Material Technologies and Practical Compliance Experience in AAV Scale Production

Recommendation 2

April 18th (Friday) 15:00-16:00

Exploration of Upstream Cultivation Processes in CGT: How to Address Long Development Cycles/Low Yields/High Costs?

Recommendation 3

April, the third week, 19:00-20:00

Industry-Academia Dialogue: Innovation and Translation of CAR-NK Therapy for Solid Tumors

In Partnership with 医麦客 IBI EXPO 2026

DianDian "Share”、“Like" and "In view", give me a little recharge~"